Quantumzyme Corp.
QTZM
Other OTC0.80
USD
+0.20
- -
CIK
0001663038
ISIN
US75955E2054
CUSIP
75955E205
Return %
Stock
S&P500
1Y
5.26
26.84
3Y
-20.00
77.03
5Y
-20.00
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Naveen Krishnarao Kulkarni
- Full Time Employees
- 1
- Sector
- Basic Materials
- Industry
- Chemicals - Specialty
- Address
- 15656 Bernardo Center Drive San Diego CA United States of America 92127
- IPO Date
- Nov 20, 2024
- CIK
- 0001663038
- Website
- quantumzymecorp.com
- Similar Companies
- Business
- Quantumzyme Corp. (QTZM) operates as a biotransformation company focused on clean and green chemistry, developing engineered enzymes and biocatalytic solutions to replace traditional chemical processes in pharmaceutical manufacturing and other industries. The company offers core services including enzyme discovery to identify promising biocatalysts for specific reactions; enzyme engineering using proprietary in silico tools such as QZyme Workbench for enhancing activity, selectivity, stability, and process efficiency; wet lab validation through whole cell or cell-free methodologies and analytical assays; and process development for optimization, scale-up, and downstream integration to deliver commercially viable, sustainable products. These solutions target sectors such as active pharmaceutical ingredients (API) production, fragrances and flavors, food, textiles, and more, emphasizing reduced hazardous waste, lower temperatures and pressures, improved yields, minimized impurities, and ESG compliance benefits over conventional metal-catalyzed methods. Founded in 2015 and headquartered at 15656 Bernardo Center Drive, Suite 801, San Diego, California, the company serves global markets with a customer-centric approach to sustainable biocatalysis. In a major strategic shift, Quantumzyme's Board of Directors approved on December 1, 2025, a proposed name change to Quantum Genesis AI Corp., pending FINRA approval and ticker symbol update, to better reflect its integration of artificial intelligence in enzyme engineering and computational modeling for eco-friendly pharmaceutical production. This rebranding aligns with ongoing R&D advancements, including published patents announced in 2025 supporting its technologies, and pursuits of partnerships, technology licensing, and joint developments to expand revenue streams across API categories. Previously known as Reliant Services, Inc., the company rebranded to Quantumzyme Corp. in March 2023.